Biotech stocks to buy now reflect a more dynamic shift in investor focus of late. Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023. The vaccine rollout was hugely successful across the globe, especially in countries like the U.S., U.K. and Germany. That said, here are three compelling biotech stocks that fit the bill and have the potential to brighten ...

Gene-editing pioneer CRISPR Therapeutics (CRSP 1.22%) stands out in this regard. Despite serious doubt from many in the scientific community, the biotech successfully advanced its gene-edited therapy Casgevy through clinical trials and subsequently won regulatory approvals in several territories such as the U.S., U.K., the European Union, and the Kingdom of Saudi Arabia for both sickle cell disease (SCD) and transfusiondependent beta-thalassemia (TDT). Morningstar analyst Rachel Elfman recently placed a $11 ...

CRISPR Therapeutics (CRSP) In Q1 of 2024, the company reported a net loss of $116.6 million, a significant increase from the prior year's $53 million. This was due to CRSP's strategic investments in R&D and market expansion for Casgevy. Despite this, the firm boasts a robust cash reserve of approximately $2.1 billion, underpinning its capacity for sustained growth and further drug approvals expected in the next two to three years. Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its pioneering cystic fibro ...

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks. Plus, At the moment, there are about 7,000 diseases caused by genetic disorders. All of which occur when a mutation affects your genes. Or, when you have the wrong amount of genetic material, as ...

Heading into today, shares of the company had gained 2.02% over the past month, lagging the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.51 per share and revenue of $89.43 million, indicating changes of -184.02% and -75.91%, respectively, compared to the previous year. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investor ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market pri ...

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...

Summary of CRISPR Therapeutics AG Conference Call Company Overview - **Company**: CRISPR Therapeutics AG (NASDAQ: CRSP) - **Date**: June 11, 2024 - **Participants**: Sam Kulkarni (CEO), Salveen Richter (Goldman Sachs) Key Points Industry and Company Focus - CRISPR Therapeutics is focusing on multiple verticals: cancer, ex-vivo non-cancer, regenerative medicine, and in vivo gene editing [2][3][5] - The company aims to balance its portfolio between rare and common diseases, believing CRISPR technology can impact both equally [2][3] Pipeline and R&D Strategy - The company has an approved drug, Casgevy, for sickle cell disease and thalassemia, marking a significant milestone [3] - CRISPR is leveraging its expertise in cell handling and technologies to develop best-in-class CAR-T therapies for cancer [3] - Regenerative medicine is viewed as an under-invested area with potential for significant impact on longevity and organ replacement [4] - In vivo gene editing is a growing focus, with plans for multiple programs targeting various organs [5] Innovation and Adaptation - CRISPR Therapeutics is committed to staying at the forefront of gene editing technology, adapting to innovations in the field [7][8] - The company has established a group called CRISPR X to explore next-generation applications of CRISPR technology [8] Delivery Technology - The company is shifting focus from viral delivery vehicles to lipid nanoparticles (LMPs) due to their safety and degradability [11][12] - LMPs are being explored for various organ systems, with ongoing challenges in non-liver applications [13] Commercial Portfolio and Casgevy Launch - The launch of Casgevy is seen as a significant opportunity, with high demand and supportive reimbursement from healthcare systems [15][16][17] - The company anticipates a long-term growth trajectory for Casgevy, differing from typical pharmaceutical launches [18] Reimbursement Landscape - The U.S. market has normalized its approach to rare disease pricing, with a better understanding of cell and gene therapies [20] - European markets are still adapting, with varying processes across countries [21] Patient Preferences - Patients show a preference for CRISPR-based therapies over traditional gene therapies when both options are available [24][25] Future Developments - The company is working on improving the preconditioning regimen for Casgevy to expand the patient population [26][27] - In vivo editing for hematopoietic cells is a long-term goal, with ongoing research into targeted LMPs [29] Cardiovascular Disease Trials - Upcoming data on cardiovascular disease trials is expected to provide insights into gene editing's effectiveness in reducing risk factors [31][32] Autoimmune Vertical - CRISPR is exploring opportunities in autoimmune diseases, particularly lupus, with a focus on CD19-directed cell therapies [34][36] - The company is well-positioned to compete in this space due to its unique approach and manufacturing capabilities [38] Oncology Portfolio - The oncology vertical remains a priority, with upcoming data expected to inform future strategies [41][44] - The company is advancing multiple CAR-T programs, including CTX-110 and CTX-112, targeting CD19 and CD70 [46] Regenerative Medicine - Regenerative medicine efforts are significant, particularly in developing stealth cells for Type 1 diabetes and other organ systems [48][50] Conclusion CRISPR Therapeutics AG is strategically positioned in the gene editing landscape, focusing on a diverse pipeline that includes cancer therapies, regenerative medicine, and autoimmune diseases. The company is adapting to technological advancements and market dynamics while maintaining a strong emphasis on patient needs and innovative delivery methods.

Core Viewpoint - CRISPR Therapeutics AG has gained attention in the market, with its stock performance showing a significant return compared to the broader market and its industry [1][2]. Stock Performance - Over the past month, CRISPR Therapeutics shares have returned +7.8%, outperforming the Zacks S&P 500 composite's +2.9% and the Zacks Medical - Biomedical and Genetics industry’s +1.2% [2]. Earnings Estimates - For the current quarter, CRISPR Therapeutics is expected to report a loss of $1.37 per share, reflecting a -39.8% change year-over-year, with a +9% revision in the consensus estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is -$5.51, indicating a -184% change from the previous year, with a +2.2% revision in the last month [5]. - For the next fiscal year, the consensus estimate is -$4.44, showing a +19.5% change from the prior year, although this estimate has decreased by -1.3% recently [6]. Revenue Estimates - The consensus sales estimate for the current quarter is $8.39 million, indicating an -88% year-over-year change [9]. - For the current fiscal year, the sales estimate is $89.43 million, reflecting a -75.9% change, while the next fiscal year’s estimate of $531.75 million indicates a +494.6% change [9]. Recent Results - In the last reported quarter, CRISPR Therapeutics generated revenues of $0.5 million, a -99.5% year-over-year decline, and reported an EPS of -$1.43 compared to -$0.67 a year ago [10]. - The company had a revenue surprise of -93.94% against the Zacks Consensus Estimate of $8.31 million, but an EPS surprise of +12.27% [10]. - CRISPR Therapeutics has beaten consensus EPS estimates in each of the last four quarters and topped revenue estimates twice during this period [11]. Valuation - CRISPR Therapeutics is graded F in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [15]. - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [13][14]. Market Outlook - The Zacks Rank for CRISPR Therapeutics is 3 (Hold), suggesting that the stock may perform in line with the broader market in the near term [7][16].

Core Viewpoint - CRISPR Therapeutics AG has experienced a 12% increase in share price over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1]. Financial Performance - In Q1 2024, CRISPR Therapeutics reported a loss of $1.43 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.63, compared to a loss of $0.67 per share in the same period last year [2]. - The company's total revenues were $0.5 million, significantly missing the Zacks Consensus Estimate of $8.3 million, and down from $100 million in the prior year, which was entirely from an upfront payment from Vertex [3]. Expense Analysis - Research and development expenses decreased by 24% year-over-year to $76.2 million, attributed to reduced external research and manufacturing costs [4]. - General and administrative expenses fell by 20% to $18.0 million, driven by lower employee-related and stock-based compensation expenses [4]. - Collaboration expenses rose by 11% year-over-year to $47.0 million, primarily due to increased commercial and manufacturing costs [4]. Cash Position - As of March 31, 2024, the company had cash, cash equivalents, marketable securities, and accounts receivables totaling $2.1 billion, up from $1.7 billion as of December 31, 2023, mainly due to proceeds from a direct offering and a $200 million milestone payment from Vertex [5]. Market Sentiment - Recent estimates for CRISPR Therapeutics have trended upward, with a consensus estimate shift of 18.14% [6]. - The company holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [8]. Industry Comparison - CRISPR Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Biogen Inc. has seen a 4.2% gain over the past month, reporting revenues of $2.29 billion, a year-over-year decline of 7% [9]. - Biogen's expected earnings for the current quarter are $3.98 per share, reflecting a 1% decrease from the previous year, with a Zacks Rank 3 (Hold) and a VGM Score of B [10].